Melanom

Prof. Reinhard Dummer, MD, University Hospital Zurich, and Prof. Olivier Michielin, MD, PhD, CHUV Lausanne, discuss the current advances and challenges in melanoma treatment with a focus on immunotherapy.

One in two patients with metastatic melanoma is alive with combination immunotherapy, according to results of the CheckMate 067 trial presented at the ESMO Congress 2019.

What remains after ASCO 2019? Listen here to what Prof. Dr. Solange Peters, Prof. Dr. Reinhard Dummer, Prof. Dr. Olivier Michielin, PD DDr. Sacha Rothschild and PD Dr. Richard Cathomas will take into their clinical practices.

For patients with metastatic melanoma who fail to durably respond to PD-1 inhibitors, fecal microbiota transplantation (FMT) combined with reintroduction of anti-PD-1 therapy seems promising.

Mohammed Milhem presents preliminary data on the combination of the TLR9 agonist CMP-001 and pembrolizumab in patients with metastatic melanoma resistant to anti-PD-1.

TLR9 agonist CMP-001-pembrolizumab combination shows early efficacy in patients with metastatic melanoma resistant to anti-PD-1.

Alexander M. M. Eggermont, MD, PhD, director general of Gustave Roussy Cancer Campus Grand Paris in Villejuif, France, talks about the key findings of the KEYNOTE-054 trial and highlights pembrolizumab's high therapeutic index.

In the KEYNOTE-054/EORTC 1325 MG-trial, patients randomized to pembrolizumab were 43 percent less likely to have recurrence.

The results of the placebo controlled double blind phase III study Keynote 054 will be presented at the AACR annual meeting.

Dr. Kilian Gust, University Clinic for Urology, Vienna, gives an overview of immunotherapy for bladder cancer and summarizes the most important data on new drugs.